Research Resources and Workforce Development for the Rocky Mountain Regional Biocontainment Laboratory at Colorado State University
科罗拉多州立大学落基山区域生物防护实验室的研究资源和劳动力发展
基本信息
- 批准号:10793907
- 负责人:
- 金额:$ 275.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-18 至 2028-07-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAccelerationAddressAdultAmericanAnimal HusbandryBiocompatible MaterialsBioterrorismCOVID-19CellsChronicClimateCollaborationsColoradoCommunicable DiseasesCommunicationCompetenceDedicationsDevelopmentDiagnosticDiseaseDomestic AnimalsEducationEducational process of instructingEducational workshopEmergency SituationEmerging Communicable DiseasesEnsureEnvironmentEquipmentEventEvolutionFaceFellowshipFoundationsFundingGoalsGrantHealth systemIn VitroInfectionInfectious AgentInformation TechnologyInfrastructureInvestmentsLaboratoriesLeadLearningMaintenanceMissionModelingModernizationMonkeypoxMonoclonal AntibodiesMycobacterium tuberculosisNational Institute of Allergy and Infectious DiseaseOperations ResearchPathogenicityPerformancePersonsProceduresPublic HealthQualifyingReagentResearchResearch PersonnelResearch SupportResource DevelopmentResourcesRodentSafetyScholars ProgramSecureSecurityServicesStructureSystemTalentsTechnologyTherapeuticToxinTrainingTraining ProgramsTraining and EducationTranslatingTuberculosisUniversitiesVaccinesVisionWorkWorkforce DevelopmentZoonosesagedbasebiodefensebiosafety level 3 facilitybiosecuritycombatcoronavirus diseasedesignimprovedin vivoindustry partnerinnovationinstrumentlaboratory facilitymass spectrometric imagingmolecular massoperationoutreachpandemic diseasepandemic pathogenpandemic potentialpathogenprofessional atmosphereprogramsrecruitresearch facilityresponsespillover eventsuccesssymposiumusabilityvaccine developmentvisiting scholar
项目摘要
Project Summary: The Rocky Mountain Regional Biocontainment Laboratory (RMRBL) at Colorado State
University (CSU) has been responsive to the national RBL mission to: 1) “Conduct research on biodefense and
emerging infectious disease agents”; 2) “Be available and prepared to assist national, state, and local public
health efforts in the event of a bioterrorism or infectious disease emergency” since its opening and full
commissioning in 2008. Researchers at the RMRBL and their collaborators rapidly pivoted in response to the
emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), working on host-derived
therapeutics, vaccines, and identifying other potential zoonotic reservoirs as spillover opportunities in wildlife
and domestic animals. Our researchers similarly pivoted this past year to work on countermeasures in
response to the re-emergence of Mpox, while also continuing to address high consequence pathogens that
have chronically plagued public health systems, such as Mycobacterium tuberculosis, the causative agent of
Tuberculosis. Beyond our demonstrated ability to rapidly address research and research service needs on
pathogens with pandemic potential, our team contributes to training, outreach, and access of our facility via
sponsored fellowships, visiting scholars’ programs, workshops, conferences, and through collaborations.
Despite these gains, our RMRBL BSL3 suites are aged, requiring constant investments to maintain safe,
secure and compliant BSL3 facilities. RMRBL BSL3 researchers, support staff, and biosafety professionals are
vulnerable to the strain of the work environment, limited resources, funding gaps, and opportunities to engage
in less risky fields equipped with cutting edge technologies. In this application, we respond to the challenges
facing the RMRBL BSL3 laboratories with 3 Cores. Core 1 includes an improved management structure,
systematic replacement of deprecating scientific instruments, and comprehensive and proactive maintenance
of existing facilities needs to ensure compliance and continuous functioning. Operation of the RMRBL BSL3 is
additionally enhanced to improve the working environment and increase consistency for operations research
support and animal husbandry staff. Core 2’s initiatives seek to develop training programs responsive to adult
learning and education best practices, ensuring improved safety and safety compliance in persons working in
the BSL3. Biosecurity upgrades will improve the safety and security climate in anticipation of new national
standards, and integration between research teams and the office of Biosafety in constructing and training in
technical standard operating procedures will accelerate safe performance and technical competence. Finally,
Core 3 synthesizes our research strengths to develop a uniquely qualified Biocontainment Research
Resources Core, bringing together opportunities to exploit team talent and perform innovative research.
Combined, our three Cores ensure that the RMRBL BSL3 facilities are always ‘warm ready’ – to face and
combat the next pathogenic pandemic threat.
项目摘要:科罗拉多州落基山地区生物防护实验室 (RMRBL)
大学 (CSU) 一直响应国家 RBL 使命:1)“开展生物防御和生物防御研究”
2) “随时准备好协助国家、州和地方公众
自其开业和全面启动以来,在发生生物恐怖主义或传染病紧急情况时的卫生努力”
2008 年投入使用。RMRBL 的研究人员及其合作者迅速转向以应对
严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 的出现,作用于宿主来源
治疗方法、疫苗以及确定其他潜在的人畜共患病宿主作为野生动物的溢出机会
我们的研究人员去年也同样致力于研究应对措施。
应对 Mpox 的重新出现,同时继续解决造成严重后果的病原体
长期困扰公共卫生系统,例如结核分枝杆菌,它是结核病的病原体
超越我们所证明的快速满足研究和研究服务需求的能力。
具有大流行潜力的病原体,我们的团队通过以下方式为培训、外展和进入我们的设施做出贡献
赞助奖学金、访问学者项目、研讨会、会议以及合作。
尽管取得了这些成就,我们的 RMRBL BSL3 套件已经过时,需要不断的投资来维护安全、
安全且合规的 BSL3 设施是 RMRBL BSL3 研究人员、支持人员和生物安全专业人员。
容易受到工作环境压力、资源有限、资金缺口和参与机会的影响
在配备尖端技术的风险较小的领域,我们应对挑战。
面对具有 3 个核心的 RMRBL BSL3 实验室,核心 1 包括改进的管理结构,
系统地更换报废的科学仪器,并进行全面主动的维护
现有设施需要确保 RMRBL BSL3 的合规性和持续运行。
进一步增强以改善工作环境并提高运筹学的一致性
Core 2 的举措旨在制定适合成人的培训计划。
学习和教育最佳实践,提高安全和安全合规性,确保工作人员
BSL3 升级将改善新国家的安全和安保氛围。
标准,以及研究团队和生物安全办公室在建设和培训方面的整合
最后,技术标准操作程序将提高安全性能和技术能力。
Core 3 综合了我们的研究优势,开发了独特且合格的生物防护研究
资源核心,汇集了开发团队人才和进行创新研究的机会。
我们的三个核心相结合,确保 RMRBL BSL3 设施始终处于“准备就绪”状态 – 面对和
对抗下一次致病性大流行威胁。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Karen Marie Dobos其他文献
Karen Marie Dobos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Karen Marie Dobos', 18)}}的其他基金
Regional Biocontainment Laboratory (RBL) Upgrade for Colorado State University (CSU)
科罗拉多州立大学 (CSU) 区域生物防护实验室 (RBL) 升级
- 批准号:
10393892 - 财政年份:2021
- 资助金额:
$ 275.15万 - 项目类别:
Regional Biocontainment Laboratory (RBL) Upgrade for Colorado State University (CSU)
科罗拉多州立大学 (CSU) 区域生物防护实验室 (RBL) 升级
- 批准号:
10631549 - 财政年份:2021
- 资助金额:
$ 275.15万 - 项目类别:
Regional Biocontainment Laboratory (RBL) Upgrade for Colorado State University (CSU)
科罗拉多州立大学 (CSU) 区域生物防护实验室 (RBL) 升级
- 批准号:
10631549 - 财政年份:2021
- 资助金额:
$ 275.15万 - 项目类别:
相似国自然基金
基于增广拉格朗日函数的加速分裂算法及其应用研究
- 批准号:12371300
- 批准年份:2023
- 资助金额:43.5 万元
- 项目类别:面上项目
肠菌源性丁酸上调IL-22促进肠干细胞增殖加速放射性肠损伤修复的机制研究
- 批准号:82304065
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于肌红蛋白构象及其氧化还原体系探究tt-DDE加速生鲜牛肉肉色劣变的分子机制
- 批准号:32372384
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于联邦学习自动超参调整的数据流通赋能加速研究
- 批准号:62302265
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
M2 TAMs分泌的OGT通过促进糖酵解过程加速肝细胞癌恶性生物学行为的机制研究
- 批准号:82360529
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
Neuroprotective Potential of Vaccination Against SARS-CoV-2 in Nonhuman Primates
SARS-CoV-2 疫苗对非人灵长类动物的神经保护潜力
- 批准号:
10646617 - 财政年份:2023
- 资助金额:
$ 275.15万 - 项目类别:
Resources and Workforce Development for Research on NIH/NIAID High Priority Pathogens at the University of Missouri Regional Biocontainment Laboratory
密苏里大学区域生物防护实验室 NIH/NIAID 高优先级病原体研究的资源和劳动力发展
- 批准号:
10793827 - 财政年份:2023
- 资助金额:
$ 275.15万 - 项目类别:
Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV Disease
优化用于预防和治疗 HSV 疾病的单克隆抗体的生成
- 批准号:
10717320 - 财政年份:2023
- 资助金额:
$ 275.15万 - 项目类别:
Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure
多维抗体工程可增强β冠状病毒医学对策的效力和广度
- 批准号:
10699866 - 财政年份:2023
- 资助金额:
$ 275.15万 - 项目类别:
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections
用于治疗 COVID-19 和其他人类冠状病毒感染的口服生物可利用抑制剂的优化
- 批准号:
10698831 - 财政年份:2023
- 资助金额:
$ 275.15万 - 项目类别: